The clean energy transition is often framed as an engineering story: better batteries, smarter grids, cheaper renewables. In reality, it is also a mining story, because electrification is metals-intensive. Solar, wind, transmission buildouts, EVs, and energy storage all rely on a steady stream of copper, nickel, cobalt, graphite, vanadium, and rare earth elements, many of […]

As the world grapples with climate change and environmental degradation, the shift towards renewable energy has never been more critical. Innovative companies are at the forefront of this transformation, developing sustainable energy solutions that reduce carbon footprints and promote a greener future. How are these companies driving the renewable energy revolution, and what impact are […]

North America’s shift toward renewable energy depends on a foundation that is often overlooked: secure access to critical metals. These minerals form the backbone of solar panels, wind turbines, advanced batteries, hydrogen systems, and electric vehicles. As demand accelerates, Canada has emerged as a central player in the strategy to build reliable, ethical, and resilient […]

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends that had been building finally started to matter in practice.

Enveric Biosciences Inc (NASDAQ: ENVB) will soon have a patent in hand for its EVM301 non-psychoactive, psychedelic-inspired drugs. The United States Patent and Trademark Office just gave Enveric a notice of allowance, thereby signalling that the agency views the patent application favourably.

Enveric Biosciences (NASDAQ:ENVB) recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) titled, “Halogenated psilocybin derivatives and methods of using.”

For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma, and addiction. That wave brought psilocybin, MDMA, ketamine clinics, and a flood of research interest. However, it was not adoptable by large patient bases.

Focus on prevention and early intervention, especially in youth. Modernize reimbursement models to reward outcomes, not volume. Invest more in innovative therapies that offer rapid, durable symptom relief. Investment is focused on low risk, late stage therapies, but what is needed to really make a difference is the higher risk innovative ideas. Rebuild trust and […]

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and polysomnography) consistent with engagement of neuroplasticity pathways, while delivering rapid and durable antidepressant effects in adults with major depressive disorder (MDD).

Boarded-up mines across the world are rusting symbols of how China seized the world’s critical minerals supply chain. Now, some of these mines—closed not because they ran dry, but by Beijing’s oversupply and price dumping—could be reopened as the Trump administration rallies nations to overthrow China’s supply chain dominance.